First drug for moderate-to-severe Alzheimer's. - Suppr | 超能文献

First drug for moderate-to-severe Alzheimer's.

出版信息

FDA Consum. 2004 Jan-Feb;38(1):3.

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

First drug for moderate-to-severe Alzheimer's.

FDA Consum. 2004 Jan-Feb;38(1):3.

2

Rationale for combination therapy with galantamine and memantine in Alzheimer's disease.加兰他敏与美金刚联合治疗阿尔茨海默病的原理。

J Clin Pharmacol. 2006 Jul;46(7 Suppl 1):17S-26S. doi: 10.1177/0091270006288735.

3

Memantine for treatment of moderate to severe Alzheimer's disease.美金刚用于治疗中度至重度阿尔茨海默病。

Issues Emerg Health Technol. 2005 Mar(64):1-4.

4

Expanded use of Aricept.

FDA Consum. 2007 Jan-Feb;41(1):3.

5

Exacerbation of myoclonus by memantine in a patient with Alzheimer disease.

J Clin Psychopharmacol. 2007 Aug;27(4):407-8. doi: 10.1097/01.jcp.0000264995.31771.05.

6

Tolerability of switching from donepezil to memantine treatment in patients with moderate to severe Alzheimer's disease.中重度阿尔茨海默病患者从多奈哌齐转换为美金刚治疗的耐受性

Int J Geriatr Psychiatry. 2008 Sep;23(9):979-81. doi: 10.1002/gps.1979.

7

New drug treatment for Alzheimer's disease. SMAC's advice on use of donepezil is contradictory.

BMJ. 1998 Oct 3;317(7163):946.

8

How do we treat people with dementia in Croatia.我们在克罗地亚如何治疗痴呆症患者。

Psychiatr Danub. 2010 Jun;22(2):363-6.

9

Improving functioning in patients with Alzheimer's.

J Psychosoc Nurs Ment Health Serv. 1998 May;36(5):11-2.

10

Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population.多奈哌齐、卡巴拉汀、加兰他敏和美金刚用于治疗成年唐氏综合征患者阿尔茨海默病性痴呆的综述：对智力残疾人群的启示

Int J Geriatr Psychiatry. 2004 Jun;19(6):509-15. doi: 10.1002/gps.1077.

引用本文的文献

1

Physiopathology of ischemic stroke and its modulation using memantine: evidence from preclinical stroke.缺血性中风的病理生理学及其使用美金刚的调节作用：来自临床前中风的证据。

Neural Regen Res. 2021 Mar;16(3):433-439. doi: 10.4103/1673-5374.293129.